pm1009
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2022 (NCT05607563)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
inhibitor - TIGIT
- Transmembrane protein PVRIGINHIBITOR
inhibitor - PVRIG
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06584071 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | Biotheus, Fudan University |
| NCT05607563 | Phase 1 | Nov 30, 2022 | Biotheus, Shanghai Oriental Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biotheus | For profit | 2 | 2 | 2 | 2022 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Shanghai Oriental Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1